Edition:
United Kingdom

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.32USD
18 Oct 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.32
Open
$5.29
Day's High
$5.35
Day's Low
$5.09
Volume
68,556
Avg. Vol
125,207
52-wk High
$7.55
52-wk Low
$4.45

Latest Key Developments (Source: Significant Developments)

Foamix Announces Additional Positive Topline Results From Third Phase 3 Trial
Monday, 1 Oct 2018 

Oct 1 (Reuters) - Foamix Pharmaceuticals Ltd ::FOAMIX ANNOUNCES ADDITIONAL POSITIVE TOPLINE RESULTS FROM THIRD PHASE 3 TRIAL (STUDY FX2017-22) EVALUATING FMX101 TOPICAL MINOCYCLINE FOAM FOR MODERATE-TO-SEVERE ACNE.FOAMIX PHARMACEUTICALS LTD - STATISTICALLY SIGNIFICANT IMPROVEMENT DEMONSTRATED IN REDUCTION OF NON-INFLAMMATORY LESIONS.FOAMIX PHARMACEUTICALS - SAFETY PROFILE OF FMX101 WAS CONSISTENT WITH THAT DETERMINED FROM TWO PRIOR PHASE 3 STUDIES.FOAMIX PHARMACEUTICALS LTD - DERMAL TOLERABILITY SCORES CONSISTENT WITH PREVIOUS PHASE 3 STUDIES.FOAMIX PHARMA-RESULTS FROM BOTH CO-PRIMARY ENDPOINTS DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT RESULTS FOR FMX101 VERSUS VEHICLE, WITH P-VALUES <0.0001.  Full Article

Foamix Pharmaceuticals Q2 Loss Per Share $0.46
Wednesday, 8 Aug 2018 

Foamix Pharmaceuticals Ltd ::FOAMIX REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.Q2 LOSS PER SHARE $0.46.Q2 EARNINGS PER SHARE VIEW $-0.56 -- THOMSON REUTERS I/B/E/S.AT JUNE 30, 2018, COMPANY HAD $56.4 MILLION IN CASH AND INVESTMENTS COMPARED TO $76.4 MILLION AT DECEMBER 31, 2017.REVENUES FOR Q2 2018 WERE $964,000 AN INCREASE OF 20.8% Q2 OF 2017.  Full Article

UPDATE 1-Foamix acne drug meets main goals in late-stage trial, shares surge

Sept 11 Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.